This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pavia, C. S.
Right arrow Articles by Cacciapuoti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pavia, C. S.
Right arrow Articles by Cacciapuoti, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 936-937, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.936-937.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease

Charles S. Pavia,1,2,* Gary P. Wormser,2 John Nowakowski,2 and Anthony Cacciapuoti3

NYCOM Microbiology and Immunodiagnostic Laboratory of the New York Institute of Technology, Old Westbury, New York 11568;1 Division of Infectious Diseases, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, New York 105952; and Schering-Plough Research Institute, Kenilworth, New Jersey 070733

Received 2 June 2000/Returned for modification 3 October 2000/Accepted 21 November 2000

The MICs of evernimicin at which 90% of Borrelia burgdorferi patient isolates were inhibited ranged from 0.1 to 0.5 µg/ml. Evernimicin was as effective as ceftriaxone against B. burgdorferi in a murine model of experimental Lyme disease. As assessed by culturing the urinary bladders of infected C3H mice, no live Borrelia isolates were recoverable following antibiotic treatment.

* Corresponding author. Mailing address: NYCOM Microbiology Laboratory, Old Westbury, NY 11568. Phone: (516) 686-3778. Fax: (516) 686-3832. E-mail: cpavia{at}iris.nyit.edu.

Antimicrobial Agents and Chemotherapy, March 2001, p. 936-937, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.936-937.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pavia, C., Inchiosa, M. A. Jr, Wormser, G. P. (2002). Efficacy of Short-Course Ceftriaxone Therapy for Borrelia burgdorferi Infection in C3H Mice. Antimicrob. Agents Chemother. 46: 132-134 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»